BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35241387)

  • 1. Comparison of Different Treatment Strategies for Blast-Phase Myeloproliferative Neoplasms.
    Castillo Tokumori F; Al Ali N; Chan O; Sallman D; Yun S; Sweet K; Padron E; Lancet J; Komrokji R; Kuykendall AT
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e521-e525. PubMed ID: 35241387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
    Gangat N; Guglielmelli P; Szuber N; Begna KH; Patnaik MM; Litzow MR; Al-Kali A; Foran JM; Palmer JM; Alkhateeb H; Elliott MA; Hanson CA; Pardanani A; Mannelli F; Vannucchi AM; Tefferi A
    Am J Hematol; 2021 Jul; 96(7):781-789. PubMed ID: 33844862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of frontline treatment approach on outcomes of myeloid blast phase CML.
    Saxena K; Jabbour E; Issa G; Sasaki K; Ravandi F; Maiti A; Daver N; Kadia T; DiNardo CD; Konopleva M; Cortes JE; Yilmaz M; Chien K; Pierce S; Kantarjian H; Short NJ
    J Hematol Oncol; 2021 Jun; 14(1):94. PubMed ID: 34130720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerated Phase of Myeloproliferative Neoplasms.
    Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
    Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
    Tefferi A; Alkhateeb H; Gangat N
    Blood Cancer J; 2023 Jul; 13(1):108. PubMed ID: 37460550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapse patterns and treatment strategies in patients receiving allogeneic hematopoietic stem cell transplantation for myeloid malignancies.
    Schuler E; Boughoufala S; Rautenberg C; Nachtkamp K; Dienst A; Fenk R; Haas R; Kondakci M; Germing U; Schroeder T; Kobbe G
    Ann Hematol; 2019 May; 98(5):1225-1235. PubMed ID: 30923997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes and predictors of survival in blast phase myeloproliferative neoplasms.
    Lancman G; Brunner A; Hoffman R; Mascarenhas J; Hobbs G
    Leuk Res; 2018 Jul; 70():49-55. PubMed ID: 29807273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase.
    Cherington C; Slack JL; Leis J; Adams RH; Reeder CB; Mikhael JR; Camoriano J; Noel P; Fauble V; Betcher J; Higgins MS; Gillette-Kent G; Tremblay LD; Peterson ME; Olsen JJ; Tibes R; Mesa RA
    Leuk Res; 2012 Sep; 36(9):1147-51. PubMed ID: 22578777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.
    Mascarenhas J; Heaney ML; Najfeld V; Hexner E; Abdel-Wahab O; Rampal R; Ravandi F; Petersen B; Roboz G; Feldman E; Podoltsev N; Douer D; Levine R; Tallman M; Hoffman R;
    Leuk Res; 2012 Dec; 36(12):1500-4. PubMed ID: 22938832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: A single center experience of 355 consecutive patients.
    Hilberink J; Hazenberg C; van den Berg E; Mulder A; Schuringa JJ; van der Helm L; de Groot M; Choi G; de Bock GH; Vellenga E; Ammatuna E; Huls G
    Leuk Res; 2019 May; 80():33-39. PubMed ID: 30954622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response.
    Begna KH; Kittur J; Gangat N; Alkhateeb H; Patnaik MS; Al-Kali A; Elliott MA; Hogan WJ; Litzow MR; Pardanani A; Hanson CA; Ketterling RP; Tefferi A
    Blood Cancer J; 2022 Jan; 12(1):7. PubMed ID: 35039473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts.
    Tefferi A; Mudireddy M; Mannelli F; Begna KH; Patnaik MM; Hanson CA; Ketterling RP; Gangat N; Yogarajah M; De Stefano V; Passamonti F; Rosti V; Finazzi MC; Rambaldi A; Bosi A; Guglielmelli P; Pardanani A; Vannucchi AM
    Leukemia; 2018 May; 32(5):1200-1210. PubMed ID: 29459662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated and Blast Phase Myeloproliferative Neoplasms.
    Jain T; Rampal RK
    Hematol Oncol Clin North Am; 2021 Apr; 35(2):325-335. PubMed ID: 33641872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accelerated and blast phase myeloproliferative neoplasms.
    Saliba AN; Gangat N
    Best Pract Res Clin Haematol; 2022 Jun; 35(2):101379. PubMed ID: 36333070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis.
    Sutter T; Schittenhelm M; Volken T; Lehmann T
    Hematology; 2023 Dec; 28(1):2206694. PubMed ID: 38078486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].
    Yan X; Qin TJ; Li B; Qu SQ; Pan LJ; Li FH; Liu NN; Xiao ZJ; Xu ZF
    Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):276-283. PubMed ID: 37356995
    [No Abstract]   [Full Text] [Related]  

  • 17. Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts.
    Bewersdorf JP; Rampal RK
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):218-224. PubMed ID: 36485103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
    Ortí G; Gras L; Zinger N; Finazzi MC; Sockel K; Robin M; Forcade E; Avenoso D; Kröger N; Finke J; Radujkovic A; Hunault-Berger M; Schroyens W; Zuckerman T; Bourhis JH; Chalandon Y; Bloor A; Schots R; de Wreede LC; Drozd-Sokolowska J; Raj K; Polverelli N; Czerw T; Hernández-Boluda JC; McLornan D; Yakoub-Agha I
    Am J Hematol; 2023 Apr; 98(4):628-638. PubMed ID: 36606718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy.
    Jabbour E; Daver N; Champlin R; Mathisen M; Oran B; Ciurea S; Khouri I; Cornelison AM; Ghanem H; Cardenas-Turanzas M; Popat U; Ravandi F; Giralt S; Garcia-Manero G; Cortes J; Kantarjian H; de Lima M
    Am J Hematol; 2014 Apr; 89(4):395-8. PubMed ID: 24375514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?
    Ruggiu M; Cassinat B; Kiladjian JJ; Raffoux E; Giraudier S; Robin M; Itzykson R; Clappier E; Michonneau D; de Fontbrune FS; de Latour RP; Ades L; Socié G
    Biol Blood Marrow Transplant; 2020 Jun; 26(6):1160-1170. PubMed ID: 32119970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.